Bone Cancer Treatment Market Growth Trajectory Through 2024-2033

Spread the love

The Bone Cancer Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Bone Cancer Treatment Market:

https://www.thebusinessresearchcompany.com/report/bone-cancer-treatment-global-market-report

According to The Business Research Company’s Bone Cancer Treatment Global Market Report 2024, The bone cancer treatment market size has grown strongly in recent years. It will grow from $1.22 billion in 2023 to $1.29 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to evolution of imaging technologies, refinement of biopsy techniques, discovery and advancement in pharmaceuticals, improvements in healthcare infrastructure, advancements in supportive care.

The bone cancer treatment market size is expected to see strong growth in the next few years. It will grow to $1.59 billion in 2028 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to changes in healthcare policies, shift towards patient-centric care models, expansion of telemedicine and remote monitoring, increasing number of cancer patients, unavailability of effective treatment and side effects. Major trends in the forecast period include government initiatives for bone cancer awareness, technological advancements in healthcare devices, increasing research and development activities, exploration and development of gene-editing techniques, increased collaboration between academia, pharmaceutical companies, and healthcare institutions.

The increasing prevalence of bone cancer is expected to drive the growth of the bone cancer treatment market. Bone cancer is a group of malignant (cancerous) tumors originating in bone tissue. It occurs when the cells in the bone divide and grow uncontrollably, forming a mass or tumor. Treatments for bone cancer are designed to offer patients with the disease several advantages. This therapy was utilized to treat several bone cancers through surgery, limb preservation, pain alleviation, better quality of life, and tumor management. For instance, in February 2023, according to reports shared by the American Society of Clinical Oncology (ASCO)., a US-based professional organization representing physicians, an estimated 3,970 (2,160 men and 1,810 women) new cases of primary bone sarcoma will be diagnosed in the US in 2023, from a counted of 400 of cases in 201 among people ages 15 to 19. Therefore, the increasing prevalence of bone cancer is driving the bone cancer treatment market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12628&type=smp

The bone cancer treatment market covered in this report is segmented –

1) By Type: Multiple Myeloma, Osteosarcoma, Chondrosarcoma, Ewing Sarcoma

2) By Treatment Type: Chemotherapy, Targeted Therapy, Radiation Therapy, Surgery, Other Treatment Types

3) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies

Innovative treatment technology approvals are a key trend gaining popularity in the bone cancer treatment market. Major companies operating in the bone cancer treatment market are focused on developing innovative treatment technology and getting approvals to strengthen their position in the market. For instance, In December 2021, Zetagen Therapeutics, a US-based clinical-stage biopharmaceutical company, received breakthrough device recognition from the U.S. Food and Drug Administration (FDA) for ZetaMet technology. This innovative technology has been specifically developed to treat metastatic bone cancer. It is a synthetic, small-molecule biologic technology developed to target and resolve metastatic bone lesions while inhibiting the growth of future lesions. The small molecule stimulates T cells and activates cells to grow healthy bones while preventing bone degradation. By specifically targeting and attaching to the bone surface, ZetaMet provides the potential for a new and effective treatment option for these patients.

The bone cancer treatment market report table of contents includes: